New Delhi49 minutes ago
- Copy link
The Ministry of Health has proposed to make some changes in the New Drugs and Clinical Trials Rules-2019. Now the public has sought suggestions on this.
The Union Ministry of Health has proposed to make some changes in New Drugs and Clinical Trials Rules-2019 to make business easier in the pharmaceutical and clinical research sector. These proposed changes were published in the Gazette of India on August 28 and now suggestions are being sought from the public.
What are the main changes?
According to the Ministry of Health, the purpose of these changes is to take a test license and simplify the process related to Biovelism/Bioqueline (BA/B). Now the existing system for the test license is being converted into a notification and intemission system.
This means that the applicants will not have to wait for the test license, except for certain high-risk drugs. They will simply inform the Central Licensing Authority and will be able to start work.
Apart from this, the processing period of application for the test license has been reduced from 90 days to 45 days. There will no longer be a need for a license for some special BA/Be Studies, instead only the authority will have to be informed.
Reforms will reduce the number of applications for the test license by about 50%.
What will be the benefit?
These changes will provide considerable relief to pharma companies and researchers. The ministry says that these reforms will reduce the number of applications for the test license by about 50%. This will help in testing medicines, research and BA/Bee studies quickly. Which will speed up the process of drug development and approval.
Also, the Central Drugs Standard Control Organization (CDSCO) will be able to use its human resource better. Which will increase the effect of regulator monitoring.
Why is this necessary?
This change is a major step towards further improvement of India in the pharmaceutical and clinical research sector. The government not only wants to benefit domestic companies by promoting ease of business. Rather, at the global level, India is also trying to make India a hub of drug development.
The public and stakeholders can give their suggestions on these proposed changes. This step will definitely give a new pace to India’s pharma sector and will further intensify the research of medicines.
Read this news too …
Claim-GST new rates will apply 5% and 18%: GST Council meeting approved 12% and 28% tax slab removal
The proposal to remove 12% and 28% tax slab has been approved on the first day of the 56th meeting of the GST Council. According to the Money Control report, two slabs will be applied only 5% and 18% to simplify the existing structure. Read full news …
Source link
[ad_3]
